HIV/TB Flashcards
Isoniazid MOA
Bactericidal against active TB
Bacteriostatic against dormant TB
Isoniazid Use
Latent TB
Active TB 1st line
Isoniazid A/E
Peripheral neuropathy (from B6 deficiency) -MC N/D Dizziness Optic neuritis Seizures
Isoniazid Pt edu
Take Vit B6 (pyridoxine) to prevent peripheral neuropathy
Limit alcohol intake
Can develop resistance
Isoniazid Toxicity
Hepatotoxic
-monitor for anorexia, malaise, yellowing of eye
may need to stop drug
Isoniazid Monitoring
SxS of hepatotoxicity
LFTs
Monthly
Direct observation therapy
Administration of each dose is carried out in the presence of an observer
By the Health department
Preferred
Intermittent Dosing
Can be done at home 2-3 times a week dosing Larger doses but less frequently No additional risk for A/E As effective as daily dosing
Latent TB Standard Tx
Isoniazid daily for 9mo - self administered
Latent TB Tx for allergy to Rifampin
Isoniazid and Rifapentine once weekly for 3 mo
DOT
Not safe for everyone
Active TB Induction phase
Eliminate actively dividing extracellular TB
Rifampin, Isoniazid, Ethambutol, Pyrazinamide x2mo
Active TB Continuation phase
Eliminate intracellular “persisters”
Rifampin and Isoniazid x4.5 mo
May last longer
Drug resistant TB
Inherent resistance, Development of resistance during tx, Inadequate drug therapy
Tx can be up to 24 mo
TB Tx Goal
Cure, prevent spread to others
Rifampin MOA
Suppresses RNA synthesis and protein synthesis
Inhibits bacterial DNA- dependent RNA polymerase
Rifampin Use
Broadspectrum abx
1st line Active Tb
Kills active and semi-dormant TB
Rifampin Drug interactions
CYP3A4 Warfarin PO BC Protease inhibitors NNRTI -All decrease effect of Rifampin
Rifampin A/E
Red-orange body fluids (every body fluid, wear glasses because it will stain contacts)
N/V/D
Flu-like symptoms
Pruritus
Rifampin Toxicity
Hepatotoxicity
Rifampin Pt edu
Use barrier method of sexual protection
Rifampin Monitoring
Drug resistance
LFTs
Pyrazinamide Use
1st line Active TB
Pyrazinamide A/E
Non Gouty polyarthralgias
N/V/D
Rash
Pyrazinamide Toxicity
Hepatotoxic
Pyrazinamide Contraindications
Liver disease
Pyrazinamide Pt edu
Limit alcohol
Manage polyarthralgias with NSAIDS (ibuprofen or aspirin)
Pyrazinamide Monitor
LFTs
-before and 2 weeks after
Ethambutol MOA
Bacteriostatic- stops from reproducing
Suppresses incorporation of mycolic acid in the cell wall
Ethambutol Use
1st line active TB
Previously treated with other drugs
Resistant to Isoniazid and/or Rifampin
Ethambutol A/E
Optic neuritis (blurred vision, constriction of visual field, disturbance of color) -especially in children
Ethambutol Contraindications
Children under 8 - due to optic neuritis
Ethambutol Pt edu
Monitor vision changes
Take food if GI upset
Ethambutol Monitoring
Monthly
Blurred vision
Color discrimination
Visual field disturbances
TB and HIV considerations
May require longer durations of treatment
At risk for developing immune reconstitution syndrome (IRIS) - exaggerated inflammatory response (another infection)
Drug interactions
TB Vaccine
BCG: only given in countries with high rates of TB and only given to children, once given, they will always test positive on a PPD
Efavirenz interaction with Rif
Least interactions
Protease inhibitors interaction with Rif
Replace Rif with Rifabutin
Raltegravir interaction with Rif
Increase dose of Raltegravir
Dolutegravir interaction with Rif
Increase Dolutegravir frequency
Maraviroc interaction with Rif
Increase Maraviroc dose
Acyclovir MOA
Inhibits viral replication by suppressing synthesis of viral DNA
Activation of acyclovir to acycloguanosine monophosphate (GMP) by thymidine kinase (GTP), the compound directly responsible for inhibiting DNA synthesis
Acyclovir Use
1st line for HSV, VZV
HSV type 2
Prophylaxis in immunocompromised pts
Not a cure, only treatment of symptoms as they happen
Acyclovir A/E IV
Phlebitis
Inflammation
Acyclovir A/E PO
N/V/D
HA
Vertigo
Acyclovir A/E Topical
Local burning/stinging
Acyclovir Toxicity
Nephrotoxicity Neurotoxicity (agitation, tremors, delirium, hallucinations, myoclonus, delirium, coma
Influenza Vax Types
Inactive- most common
Recombinant- not made with egg
Live attenuated- nose spray
Influenza Vax Protection
Begins 1-2 weeks after vax
Last 6 mo
Influenza Vax Use
Anyone greater than 6 mo old
Pregnant- only inactivated
Children 2-8 need to get it 2 times to be effective
Influenza Vax A/E Inactivated
Soreness at site Fever Myalgia Malaise Guillain-barre syndrome
Influenza Vax A/E Live
Runny nose Congestion Sore throat/ cough HA Fever Myalgia
Influenza Vax precautions
Do not vaccinate person who is acutely ill (fever greater than 100)
Can vaccinate person who is minor illness (fever less than 100)
Influenza Vax Contraindications
Hypersensitivity to eggs - inactivated
Severe reaction to influenza vax in the past
Guillain-barre syndrome
Oseltamivir Use
Can improve symptoms and duration of flu A/B
Not for sx past 48hr
Can be prophylaxis
Oseltamivir A/E
N/V Hypersensitivity reaction Anaphylaxis Rash Neuropsychiatric effects (hallucinations in children)
Oseltamivir Drug interaction
Blunts vax response
D/C: 2 days before live vax and for 2 weeks after vax
Oseltamivir Pt edu
Take with food for N/V
Nucleoside Reverse Transcriptase Inhibitors (NRTI) Drugs
Abacavir
Tenofovir
Emtricitabine
NRTI MOA
Incorporates into viral DNA strands by reverse transcriptase terminating DNA synthesis
Blocks enzyme of HIV it needs to make copies of itself
Prevents DNA strands from growing
NRTI
HIV
NRTI A/E
Hepatosteatosis (mitochondrial breakdown of fatty acids and deposited onto the liver) Lactic acidosis (mitochondrial breakdown- Vs, and ABG monitoring, Nausea, fatigue, respiratory acidosis) Lipoatrophy (redistribution of fat in the shoulder blades, face and neck)
Abacavir A/E
Hypersensitivity reaction
Abacavir Drug interaction
Ganciclovir/Valganciclovir
Abacavir Testing done before treatment
HLA-B*5701 genetic testing
NRTI Monitoring
LFTs
Tenofovir A/E
Osteomalacia
Renal insufficiency
N/V
Tenofovir Drug interactions
Didanosine
Tenofovir Nursing considerations
Adjust dose for renal impairment
Already has a phosphate group attached
Tenofovir Monitoring
Cr clearance
Emtricitabine A/E
Hyperpigmentation of hands and soles of feet
Emtricitabine Drug interaction
Lamivudine
Emtricitabine Nursing considerations
Adjust dose for renal impairment
Emtricitabine Monitoring
Cr clearance
Test for HIV pt before starting Tx
CD4 count Plasma HIV RNA (viral load) Genotype resistant test Hep A, B, C STIs
Initial phase of HIV
High rate of replication
Experience flu-like acute retroviral symptoms
Middle phase of HIV
Can be up to 10 years
Prolonged clinical latency
Low HIV blood levels
Asymptomatic
Latent phase of HIV
CD4 levels typically fall below 200
AIDS and opportunistic infections more likely to occur
Peripheral neuropathy
CNS problems
HIV Goals
Reduce HIV associated morbidity Prolong the duration and quality of life Suppress HIV viral load Restore and maintain immune function Prevent transmission No cure
Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Drug
Efavirenz
Efavirenz MOA
Binds directly and non-competitively to reverse transcriptase, blocking DNA polymerase activity
Blocks DNA as it activates
Prevents DNA strand altogether
Efavirenz Use
1st line therapy for HIV
Efavirenz A/E
Rash
Increased liver enzymes
CNS effects (vivid dreams/ nightmare)
Dizziness/drowsiness with food
Efavirenz Toxicity
Hepatotoxicity
Efavirenz Drug interactions
CYP3A4
BC
St. John Wort
Efavirenz Contraindication
Pregnancy
Efavirenz Pt edu
Take on empty stomach at bedtime
Use barrier method of protection of contraception
Efavirenz Monitoring
LFTs
NNRTIs
Not structurally related to nucleoside
Active when administered
Take on empty stomach
X preggo
NRTIs
Chemically related to nucleoside and nucleotide Intracellular conversion Fewer drug interactions W/wo food ✔︎ preggo
Protease inhibitor Drug
Lopinavir/Ritonavir
Protease inhibitor MOA
Prevents HIV protease enzyme from cleaving polyprotein into individual proteins responsible for assembling new viron
Prevents budding off and infeeting new cells
Protease inhibitor A/E
GI effects N/V/D
Increased bleeding with hemophilia
Lipodystrophy
Hyperlipidemia
Hyperglycemia- new onset DM ~ 2 mo after start of tx
Increased serum transaminases - liver injury
Protease inhibitor Drug interactions
CYP3A4
-Statins: use something else to control HLD
Usually given with 2 reverse transcriptase inhibitors which is part of antiretroviral management
Protease inhibitor Use
HIV
Lopinavir/Ritonavir MOA
Lopinavir is active
Ritonavir boosts effects of lopinavir
Lopinavir/Ritonavir A/E
Diarrhea
PR/QT prolongation (AV block/ Torsades de Pointes)
Lopinavir/Ritonavir Drug interactions
BC
Disulfiram
Metronidazole
Lopinavir/Ritonavir Contraindication
Those who have a HST of heart problems and or take drugs that cause heart problems (zofran)
Lopinavir/Ritonavir Pt edu
Take with food
Refrigerate
CCR5 Antagonist Drug
Maraviroc
Maraviroc MOA
Blocks entry into the cell
Maraviroc Use
Must have genotype testing done for CCR5 trophic (HIV strain must have CCR5 trophic before initiation)
Must be combined
BID
Mostly used when other resistance
Integrase inhibitor Drug
Raltegravir
Raltegravir MOA
Inhibits integrase, preventing incorporation of viral DNA into hose genome
Metabolized by uridine diphosphate glucuronosyltransferase
Raltegravir Use
1st line in combo for HIV
Resistant strains
Raltegravir A/E
Insomnia
HA
Hypersensitivity reaction (SJS)
Raltegravir Drug interactions
PPI: Increase plasma drug level
Rifampin: Would have to double dose of Rifampin
Raltegravir Toxicity
Hepatotoxicity
Raltegravir Monitoring
LFTs